IL271966B2 - A universal vaccine based on shared neoantigens for the prevention and treatment of cancer (MICRO SATELLITE INSTABLE (MSI)) - Google Patents

A universal vaccine based on shared neoantigens for the prevention and treatment of cancer (MICRO SATELLITE INSTABLE (MSI))

Info

Publication number
IL271966B2
IL271966B2 IL271966A IL27196620A IL271966B2 IL 271966 B2 IL271966 B2 IL 271966B2 IL 271966 A IL271966 A IL 271966A IL 27196620 A IL27196620 A IL 27196620A IL 271966 B2 IL271966 B2 IL 271966B2
Authority
IL
Israel
Prior art keywords
cancer
fsps
fsp
cvp
collection
Prior art date
Application number
IL271966A
Other languages
English (en)
Hebrew (he)
Other versions
IL271966A (en
IL271966B1 (en
Inventor
Nicosia Alfredo
Lahm Armin
Scarselli Elisa
LEONI Guido
Original Assignee
Nouscom Ag
Nicosia Alfredo
Lahm Armin
Scarselli Elisa
LEONI Guido
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag, Nicosia Alfredo, Lahm Armin, Scarselli Elisa, LEONI Guido filed Critical Nouscom Ag
Publication of IL271966A publication Critical patent/IL271966A/en
Publication of IL271966B1 publication Critical patent/IL271966B1/en
Publication of IL271966B2 publication Critical patent/IL271966B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10Sequence alignment; Homology search
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL271966A 2017-07-12 2018-07-12 A universal vaccine based on shared neoantigens for the prevention and treatment of cancer (MICRO SATELLITE INSTABLE (MSI)) IL271966B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17181026 2017-07-12
PCT/EP2018/069032 WO2019012082A1 (en) 2017-07-12 2018-07-12 UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI)

Publications (3)

Publication Number Publication Date
IL271966A IL271966A (en) 2020-02-27
IL271966B1 IL271966B1 (en) 2024-09-01
IL271966B2 true IL271966B2 (en) 2025-01-01

Family

ID=59366234

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271966A IL271966B2 (en) 2017-07-12 2018-07-12 A universal vaccine based on shared neoantigens for the prevention and treatment of cancer (MICRO SATELLITE INSTABLE (MSI))

Country Status (19)

Country Link
US (1) US11578109B2 (OSRAM)
EP (1) EP3652606B1 (OSRAM)
JP (1) JP7274223B2 (OSRAM)
KR (1) KR102709778B1 (OSRAM)
CN (1) CN111328420B (OSRAM)
AU (1) AU2018298849B2 (OSRAM)
BR (1) BR112020000590A2 (OSRAM)
CA (1) CA3069047A1 (OSRAM)
DK (1) DK3652606T5 (OSRAM)
ES (1) ES2940087T3 (OSRAM)
FI (1) FI3652606T3 (OSRAM)
HU (1) HUE061840T2 (OSRAM)
IL (1) IL271966B2 (OSRAM)
MX (1) MX2020000413A (OSRAM)
NZ (1) NZ759940A (OSRAM)
PL (1) PL3652606T3 (OSRAM)
PT (1) PT3652606T (OSRAM)
SG (1) SG11202000250PA (OSRAM)
WO (1) WO2019012082A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3827263A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
WO2020022903A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
CA3106567A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
EP3827261A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
US20210187088A1 (en) 2018-07-26 2021-06-24 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220008525A1 (en) * 2019-02-07 2022-01-13 Arizona Board Of Regents On Behalf Of Arizona State University Cancer specific frameshift vaccines
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
WO2021228999A1 (en) * 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP2024516542A (ja) * 2021-04-06 2024-04-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Mhcクラスiペプチドを含む方法および組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187508A2 (en) * 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
WO2003087162A2 (en) * 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
US20060160090A1 (en) * 2003-04-11 2006-07-20 Macina Robert A Composition splice variants and methods relating to cancer specific genes and proteins
CN1824325A (zh) * 2005-12-16 2006-08-30 武汉大学 人乳头病毒dna嵌合疫苗及制备方法和应用
KR101454287B1 (ko) * 2006-10-17 2014-11-04 온코세라피 사이언스 가부시키가이샤 Mphosph1 또는 depdc1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
SG175407A1 (en) 2009-05-29 2011-11-28 Morphosys Ag A collection and methods for its use
JP2013523084A (ja) * 2010-04-09 2013-06-17 オンコセラピー・サイエンス株式会社 Cdca5ペプチドおよびそれを含むワクチン
CA2830787C (en) * 2011-03-24 2019-11-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dominant negative hsp110 mutant and its use in prognosing and treating cancers
DK2742133T3 (en) * 2011-08-12 2017-12-04 Oncotherapy Science Inc MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THESE
BR112015013737B1 (pt) * 2012-12-13 2021-07-27 Ruprecht-Karls-Universitãt Heidelberg Peptídeos com alteração do quadro de leitura msiespecífico (fsp) para a prevenção e tratamento do câncer
US9205140B2 (en) * 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクRuprecht−Karls−Universitaet Heidelberg がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp)
WO2014099979A2 (en) * 2012-12-17 2014-06-26 Virginia Tech Intellectual Properties, Inc. Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci
WO2015112930A1 (en) * 2014-01-27 2015-07-30 Yale University Novel methods of identifying patients responsive to immunotherapeutic strategies
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用
US12150980B2 (en) * 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187508A2 (en) * 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SCHWITALLE YVETTE ET AL, " IMMUNOGENIC PEPTIDES GENERATED BY FRAMESHIFT MUTATIONS IN DNA MISMATCH REPAIR-DEFICIENT CANCER CELLS.", 25 November 2004 (2004-11-25) *
SHEN LUHUI ET AL, " ABSTRACT 469: PROGRESS TOWARDS DEVELOPING A UNIVERSAL, PROPHYLACTIC CANCER VACCINE.", 1 April 2013 (2013-04-01) *
WOERNER S M ET AL, " SYSTEMATIC IDENTIFICATION OF GENES WITH CODING MICROSATELLITES MUTATED IN DNA MISMATCH REPAIR-DEFICIENT CANCER CELLS", 1 October 2001 (2001-10-01) *

Also Published As

Publication number Publication date
CN111328420B (zh) 2023-07-25
IL271966A (en) 2020-02-27
US20200222519A1 (en) 2020-07-16
FI3652606T3 (fi) 2023-03-16
KR102709778B1 (ko) 2024-09-26
BR112020000590A2 (pt) 2020-07-14
US11578109B2 (en) 2023-02-14
MX2020000413A (es) 2020-09-28
EP3652606B1 (en) 2023-01-11
JP7274223B2 (ja) 2023-05-16
RU2019144505A3 (OSRAM) 2021-08-12
HUE061840T2 (hu) 2023-08-28
WO2019012082A1 (en) 2019-01-17
IL271966B1 (en) 2024-09-01
RU2019144505A (ru) 2021-08-12
JP2020532288A (ja) 2020-11-12
AU2018298849B2 (en) 2022-07-14
EP3652606A1 (en) 2020-05-20
AU2018298849A1 (en) 2020-01-02
PT3652606T (pt) 2023-03-16
SG11202000250PA (en) 2020-02-27
CN111328420A (zh) 2020-06-23
CA3069047A1 (en) 2019-01-17
KR20200029443A (ko) 2020-03-18
NZ759940A (en) 2023-07-28
DK3652606T3 (da) 2023-03-13
PL3652606T3 (pl) 2023-04-24
DK3652606T5 (da) 2024-08-26
ES2940087T3 (es) 2023-05-03
WO2019012082A9 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
US11578109B2 (en) Universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers
RU2644201C2 (ru) Вакцины против hpv
RU2019119272A (ru) Вирусная доставка неоантигенов
JP7551495B2 (ja) Hpvワクチン
JP2004506410A (ja) 合成ぺプチド及びその使用
JP2003509035A (ja) ポリエピトープポリペプチドをコードする核酸
Mennuni et al. Efficient induction of T‐cell responses to carcinoembryonic antigen by a heterologous prime‐boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA
CA3109541A1 (en) Teleost invariant chain cancer vaccine
US20070104685A1 (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
JP2021523712A (ja) 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ(rmva)ワクチン及びその調製方法
JP7025119B2 (ja) アスパラギン酸-β-ヒドロキシラーゼは腫瘍においてエピトープ特異的T細胞応答を誘導する
HK40029760B (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
HK40029760A (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
Restifo et al. Enhancing the recognition of tumor associated antigens
AU2016335070B2 (en) Polyepitope constructs for use in immunotherapy
Bazhan et al. Design of Artificial Immunogens Containing T-Cell Epitopes of Ebola Virus Proteins
ZA200508013B (en) Synthetic gene encoding human carcinoembryonic antigen and use thereof
HK1002055B (zh) 多表位疫苗
HK1002055A1 (en) Polyepitope vaccines